Targeting Tumour Neoepitopes with Monoclonal Antibodies

Time: 2:00 pm
day: Day Two


  • Employing a unique cancer vaccine platform to develop monoclonal antibodies against functional tumour neo-antigens
  • Utilising innovative technologies and expertise in immunology, in addition to unique antibody display platforms with an automated high throughput screening
  • Using these antibodies to identify the precise neoantigen targeted